Literature DB >> 7198474

[Biotransformation of tramadol in man and animal (author's transl)].

W Lintz, S Erlaçin, E Frankus, H Uragg.   

Abstract

Following p.o. administration of 14C-labelled rac.-1-(e)-(m-methoxyphenyl)-2-(e)-dimethylaminomethyl-cyclohexan-1-(a)-ol hydrochloride (tramadol hydrochloride, CG 315, Tramal) to mice, hamsters, rats, guinea pigs, rabbits, dogs and man the metabolic pathways were investigated and the results compared. After synthesis of the reference substances the metabolites were identified by co-chromatography using both TLC (thin-layer chromatography) and HPLC (high-performance liquid chromatography) methods, by co-crystallization and by gas chromatography-mass spectrometry. In all species the main metabolic pathways are N- and O-demethylation (phase I reactions) and conjugation of O-demethylated compounds (phase II reactions). 11 metabolites are known, 5 arising by phase I reactions (M1 to M5) and 6 by phase II reactions (glucuronides and sulfates of M1, M4 and M5). The 5 phase I metabolites are mono-O-demethyl-tramadol (M1), mono-N-demethyl-tramadol (M2), di-N-demethyl-tramadol (M3), tri-N,O-demethyl-tramadol (M4) and di-N,O-demethyl-tramadol (M5). The biotransformation scheme of tramadol is qualitatively identical in man, dog, rabbit, guinea pig, rat, hamster and mouse. In all species M1 and M1-conjugates, M5 and M5-conjugates and M2 are the main metabolites, whereas M3, M4 and M4-conjugates were only formed in minor quantities. Following p.o. administration to man and animals 14C-tramadol are rapidly and almost completely absorbed. The unchanged drug and metabolites are mainly excreted via kidneys. The cumulative renal excretion of total radioactivity accounts for approximately 90% in man and varies from 86 to 100% in mouse, hamster, rat, guinea pig, rabbit and dog; the residual of the applied radioactivity appears in the feces. Apparently tramadol is metabolized much more rapidly in animals than in man. For that reason there are appreciable differences between man and animals in the amount of tramadol excreted unchanged in the urine (about 30% and 1% of the p.o. dose, respectively). After incubation with beta-glucuronidase and arylsulfatase at least 81% of the excreted radioactivity could be extracted from the urine of man animals (with the exception of the guinea pig and the rabbit). In man all extractable metabolites were identified.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7198474

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  42 in total

Review 1.  The role of tramadol in cancer pain treatment--a review.

Authors:  Wojciech Leppert; Jacek Łuczak
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

3.  Identification of canine cytochrome P-450s (CYPs) metabolizing the tramadol (+)-M1 and (+)-M2 metabolites to the tramadol (+)-M5 metabolite in dog liver microsomes.

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Darren Schnider; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  J Vet Pharmacol Ther       Date:  2018-08-16       Impact factor: 1.786

4.  Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates.

Authors:  H L Claahsen-van der Grinten; I Verbruggen; P P van den Berg; J M J Sporken; L A A Kollée
Journal:  Eur J Clin Pharmacol       Date:  2005-07-09       Impact factor: 2.953

5.  Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.

Authors:  Nora M Hagelberg; Tuukka Saarikoski; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Miia Turpeinen; Mika Scheinin; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-10-26       Impact factor: 2.953

6.  Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein.

Authors:  Mouna Kanaan; Youssef Daali; Pierre Dayer; Jules Desmeules
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-05-26       Impact factor: 4.080

Review 7.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

8.  Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro.

Authors:  B Driessen; W Reimann; H Giertz
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

9.  Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study.

Authors:  K A Payne; J A Roelofse; E A Shipton
Journal:  Anesth Prog       Date:  2002

10.  Effects of the central analgesic tramadol and its main metabolite, O-desmethyltramadol, on rat locus coeruleus neurones.

Authors:  J Sevcik; K Nieber; B Driessen; P Illes
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.